Viewing Study NCT05092360

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:06 AM
Ignite Modification Date: 2026-05-19 @ 3:54 PM
Study NCT ID: NCT05092360
Status: TERMINATED
Last Update Posted: 2025-08-28
First Post: 2021-10-13
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Sponsor: Mural Oncology, Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Platinum-resistant Ovarian Cancer View
None Fallopian Tube Cancer View
None Primary Peritoneal Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PROC View
None EOC View
None ALKS 4230 View
None IL-2 View
None Ovarian Cancer View
None KEYNOTE-C71 View
None Platinum Resistant View
None Epithelian Ovarian Cancer View
None Nemvaleukin alfa View
None Pembrolizumab View
None ARTISTRY-7 View
None ART-7 View
None paclitaxel View
None pegylated liposoma doxorubicin View
None PLD View
None topotecan View
None gemzar View
None gemcitabine View